Federal judge stops compounded copies of Lilly weight loss, diabetes drugs
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed decision
US judge bars copies of Lilly weight-loss drug
(Reuters) - A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.
New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous value they offer.
Public health group warns about fake weight loss drugs
As weight loss drugs continue to grow in popularity in the U.S., some health leaders are warning about fake drugs on the market. Drugs like Zepbound, Ozempic, Mounjaro and
Eli Lilly cuts prices for Zepbound weight-loss drug again
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.
US judge ruling for FDA bars copies of Lilly weight loss drug
U.S. regulations allow compounding pharmacies to manufacture and sell large quantities of brand-name medicines only if they are in short supply. The FDA first announced in October that Lilly's Zepbound and diabetes drug Mounjaro, both known chemically as tirzepatide, were out of shortage before reaffirming that decision in December.
Judge makes surprise ruling in weight-loss-drug case
Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues. The San Francisco telehealth company could've used some strong medicine on March 6 when its shares took sick amid a court ruling and stepped up competition involving weight-loss drugs.
Modern Healthcare11h
Teladoc, LifeMD partner with Eli Lilly on GLP-1s
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
These discounted versions of popular weight-loss drugs are going away: What to know
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
ConsumerAffairs2d
GLP-1 insurance coverage worsened at start of 2025, report says
Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...
The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions ...
Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...